BIIB
Price
$185.01
Change
-$0.00 (-0.00%)
Updated
Oct 28 closing price
One day until earnings call
BMY
Price
$52.64
Change
-$0.00 (-0.00%)
Updated
Oct 28 closing price
2 days until earnings call
Ad is loading...

BIIB vs BMY

Header iconBIIB vs BMY Comparison
Open Charts BIIB vs BMYBanner chart's image
Biogen
Price$185.01
Change-$0.00 (-0.00%)
Volume$1.89M
CapitalizationN/A
Bristol-Myers Squibb
Price$52.64
Change-$0.00 (-0.00%)
Volume$8.53M
CapitalizationN/A
View a ticker or compare two or three
BIIB vs BMY Comparison Chart
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
BMY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
BIIB vs. BMY commentary
Oct 30, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Buy and BMY is a Buy.

COMPARISON
Comparison
Oct 30, 2024
Stock price -- (BIIB: $185.01 vs. BMY: $52.64)
Brand notoriety: BIIB and BMY are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 159% vs. BMY: 75%
Market capitalization -- BIIB: $31.34B vs. BMY: $109.66B
BIIB [@Pharmaceuticals: Major] is valued at $31.34B. BMY’s [@Pharmaceuticals: Major] market capitalization is $109.66B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 1 FA rating(s) are green whileBMY’s FA Score has 2 green FA rating(s).

  • BIIB’s FA Score: 1 green, 4 red.
  • BMY’s FA Score: 2 green, 3 red.
According to our system of comparison, BMY is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 5 TA indicator(s) are bullish while BMY’s TA Score has 2 bullish TA indicator(s).

  • BIIB’s TA Score: 5 bullish, 3 bearish.
  • BMY’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than BMY.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +0.19% price change this week, while BMY (@Pharmaceuticals: Major) price change was +1.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.02%. For the same industry, the average monthly price growth was -0.06%, and the average quarterly price growth was +8.84%.

Reported Earning Dates

BIIB is expected to report earnings on Jan 30, 2025.

BMY is expected to report earnings on Feb 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-0.02% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BMY($110B) has a higher market cap than BIIB($31.3B). BIIB has higher P/E ratio than BMY: BIIB (26.95) vs BMY (13.73). BMY YTD gains are higher at: 7.780 vs. BIIB (-28.504). BMY has higher annual earnings (EBITDA): 19.4B vs. BIIB (2.04B). BMY has more cash in the bank: 12.3B vs. BIIB (1.05B). BIIB has less debt than BMY: BIIB (7.34B) vs BMY (41.5B). BMY has higher revenues than BIIB: BMY (45B) vs BIIB (9.84B).
BIIBBMYBIIB / BMY
Capitalization31.3B110B28%
EBITDA2.04B19.4B11%
Gain YTD-28.5047.780-366%
P/E Ratio26.9513.73196%
Revenue9.84B45B22%
Total Cash1.05B12.3B9%
Total Debt7.34B41.5B18%
FUNDAMENTALS RATINGS
BIIB vs BMY: Fundamental Ratings
BIIB
BMY
OUTLOOK RATING
1..100
485
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
7
Undervalued
PROFIT vs RISK RATING
1..100
10070
SMR RATING
1..100
7795
PRICE GROWTH RATING
1..100
6331
P/E GROWTH RATING
1..100
1892
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMY's Valuation (7) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (96) in the Biotechnology industry. This means that BMY’s stock grew significantly faster than BIIB’s over the last 12 months.

BMY's Profit vs Risk Rating (70) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that BMY’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's SMR Rating (77) in the Biotechnology industry is in the same range as BMY (95) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to BMY’s over the last 12 months.

BMY's Price Growth Rating (31) in the Pharmaceuticals Major industry is in the same range as BIIB (63) in the Biotechnology industry. This means that BMY’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's P/E Growth Rating (18) in the Biotechnology industry is significantly better than the same rating for BMY (92) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew significantly faster than BMY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBBMY
RSI
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
55%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
60%
Bearish Trend 2 days ago
51%
Momentum
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
52%
MACD
ODDS (%)
Bullish Trend 2 days ago
54%
Bearish Trend 2 days ago
46%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 2 days ago
53%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
53%
Advances
ODDS (%)
Bullish Trend 12 days ago
53%
Bullish Trend 7 days ago
55%
Declines
ODDS (%)
Bearish Trend 14 days ago
67%
Bearish Trend 5 days ago
55%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
60%
Bearish Trend 2 days ago
59%
Aroon
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 2 days ago
51%
View a ticker or compare two or three
Ad is loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
BMY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME22.732.16
+10.50%
GameStop Corp
BTC.X69907.7600001978.460900
+2.91%
Bitcoin cryptocurrency
AAPL233.401.99
+0.86%
Apple
SPY580.831.79
+0.31%
SPDR® S&P 500® ETF Trust
TSLA262.51-6.68
-2.48%
Tesla

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+1.83%
AMGN - BIIB
42%
Loosely correlated
+0.06%
OGN - BIIB
36%
Loosely correlated
+1.75%
GILD - BIIB
32%
Poorly correlated
-0.27%
AZN - BIIB
32%
Poorly correlated
+1.25%
NVS - BIIB
29%
Poorly correlated
+1.62%
More

BMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMY has been loosely correlated with JNJ. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then JNJ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMY
1D Price
Change %
BMY100%
+1.39%
JNJ - BMY
49%
Loosely correlated
+0.45%
PFE - BMY
37%
Loosely correlated
+1.44%
GILD - BMY
36%
Loosely correlated
-0.27%
ABBV - BMY
35%
Loosely correlated
+0.97%
RHHBY - BMY
29%
Poorly correlated
-0.64%
More